

Documents relating to this proceeding are available for public inspection at the Commission's Public Document Room, the Gelman Building, 2120 L Street, NW., Washington, DC 20037.

Dated: November 20, 1995.

For the Atomic Safety and Licensing Board.

G. Paul Bollwerk, III,

*Chairman, Administrative Judge.*

[FR Doc. 95-28833 Filed 11-24-95; 8:45 am]

BILLING CODE 7590-01-P

### **Nominations of New Member of the Advisory Committee on the Medical Uses of Isotopes**

**AGENCY:** U.S. Nuclear Regulatory Commission.

**ACTION:** Call for nominations.

**SUMMARY:** The U.S. Nuclear Regulatory Commission is inviting nominations, of individuals who are qualified as nuclear medicine physicians, for a position on the Advisory Committee on the Medical Uses of Isotopes (ACMUI).

**DATES:** Nominations are due January 26, 1996.

**ADDRESSES:** Submit nominations to: The Office of Personnel, ATTN: Ms. Jude Himmelberg, Mail Stop T2D32, U.S. Nuclear Regulatory Commission, Washington, DC 20555.

**FOR FURTHER INFORMATION, CONTACT:** Josephine M. Piccone, Ph.D., Office of Nuclear Material Safety and Safeguards, U.S. Nuclear Regulatory Commission, Washington, DC 20555, Telephone: 301-415-7270.

**SUPPLEMENTARY INFORMATION:** The ACMUI advises the NRC on policy and technical issues that arise in regulating the medical use of byproduct material for diagnosis and therapy. Responsibilities include providing guidance and comments on changes in NRC rules, regulations, and guides concerning medical use; evaluating certain non-routine uses of byproduct material for medical use; and providing technical assistance in licensing, inspection, and enforcement cases.

Committee members possess the medical and technical skills needed to address evolving issues. Currently the membership of the ACMUI consists of five practicing physicians; a physician representing the U.S. Department of Health and Human Services, Food and Drug Administration; one nuclear pharmacist; one medical physicist; one representative with the States' perspective; one patients' rights and care advocate; and one health care administrator. The specialties of the physicians on the ACMUI are: nuclear

cardiology (one); therapeutic radiology, with expertise in teletherapy and brachytherapy (two); nuclear medicine research (one); and nuclear medicine (one). The term of the current nuclear medicine physician member is scheduled to end September 1996.

Nominations for the position of radiation therapy technologist/medical dosimetrist and medical physicist with expertise in radiation therapy are currently being evaluated.

NRC is soliciting nominations of persons who are qualified as nuclear medicine physicians. Persons having the aforementioned qualifications are encouraged to apply.

Nominees must include four copies of their resume, describing their educational and professional qualifications, and provide their current address and telephone number.

All new committee members will serve a 2-year term, with possible reappointment to two additional 2-year terms.

Nominees must be U.S. citizens and be able to devote approximately 80 hours per year to committee business. Members will be compensated and reimbursed for travel (including per diem in lieu of subsistence), secretarial, and correspondence expenses. Nominees will undergo a security background check and will be required to complete financial disclosure statements, to avoid conflict-of-interest issues.

Dated at Washington, DC, this 20th day of November, 1995.

For the U.S. Nuclear Regulatory Commission.

Andrew L. Bates,

*Advisory Committee Management Officer,  
Office of the Secretary of the Commission.*

[FR Doc. 95-28834 Filed 11-24-95; 8:45 am]

BILLING CODE 7590-01-P

[Docket No: 040-08948 040-07397]

### **Information Meeting Concerning the Development of an Environmental Impact Statement for the Shieldalloy Metallurgical Corporation, Cambridge, Ohio, Facility**

**AGENCY:** Nuclear Regulatory Commission.

**ACTION:** Notice of meeting.

**SUMMARY:** This notice is to inform the public of a meeting to discuss the U. S. Nuclear Regulatory Commission's process for decommissioning nuclear facilities and the development of an environmental impact statement (EIS) for the Shieldalloy Metallurgical Corporation (SMC), Cambridge, Ohio, facility, one of the key steps in this

process. A brief status report will also be provided for the remediation of properties, in the Cambridge, Ohio, area, that contain slag that may have been removed from the Shieldalloy facility. Interested individuals are invited to attend this meeting. NRC, SMC, Cyprus Foote Mineral Company (CFMC), State and local officials, and citizen groups will share information concerning these topics in a facilitated roundtable discussion.

### **Background**

The SMC facility processes ores for the production of metal alloys. The SMC license (SMB-1507) authorizes the possession of the radionuclides uranium and thorium as contaminants in slag from previous operations at this site. The previous owners (Vanadium Corporation of America, now Newmont Mining Corporation, and Foote Mineral Company (FMC), now Cyprus Foote Mineral Company) had processed an ore containing licensable quantities of natural uranium and thorium, and radionuclides resulting from their radioactive decay. The processing of this ore started in the late 1950s and ended in the early 1970s. In processing this ore to produce metal alloys, the radioactive material contained in the ore was segregated into slag. The waste slag is currently in a dense, rock-like form and stored in two piles on the site. In 1987, SMC purchased the facility from FMC. SMC continues to process ores for the production of metal alloys. However, these ores do not contain licensable quantities of radioactive material. With the exception of radioactive contamination that exists in, or originated from, the two slag piles, SMC has remediated the radioactive contamination at the site. NRC staff is developing an EIS to evaluate alternatives associated with decommissioning the slag piles.

In a possibly related matter, it was determined, in 1993, that slag from the site, when it was owned by FMC, may have been used as fill at offsite locations. Radiation surveys and slag analyses that NRC conducted in 1994 indicate that the slag does not pose an immediate health and safety risk to residents. However, some action may be necessary at specific locations, to minimize the long-term risk associated with the slag. In a letter dated January 25, 1995, SMC requested that the EIS be modified to include an analysis of the relocation of the offsite slag to the SMC, Cambridge, Ohio, site.

In addition to the issues that fall under NRC's jurisdiction, there are other environmental issues, associated with decommissioning the Cambridge site,

that are regulated by State and other Federal agencies, including the U.S. Environmental Protection Agency, the Ohio Environmental Protection Agency, and the Ohio Department of Health. As a result of these other environmental issues, SMC and CFMC are conducting a remedial investigation/feasibility study (RI/FS) for the SMC, Cambridge, Ohio, facility. In a letter dated July 5, 1995, SMC requested that the EIS be further expanded to examine the impacts of depositing, on one of the slag piles, contaminated soils and sediments resulting from site remediation under the RI/FS.<sup>1</sup>

A notice of intent to revise the scope of this EIS—to consider the impacts of depositing soils and sediments on the West Slag Pile and relocating slag from offsite—was published in the Federal Register on August 21, 1995 (60 FR 43477). In addition, SMC has stated that some of the slag may have a commercial use. Further information is needed from SMC to evaluate the impacts of this use. An additional expansion in scope may be needed to include this alternative.

The NRC hopes to accomplish three main objectives at the December 5, 1995, meeting:

- To describe NRC's overall decommissioning process for a nuclear facility, with an emphasis on opportunities for public involvement and participation, and the EIS portion of the process.
- To provide a status report on the EIS, including the additional alternatives of returning offsite slag and contaminated soils and sediments to the existing slag piles for permanent disposal.
- To provide a brief status report on the offsite slag situation.

NRC anticipates that the information provided at the public meeting will stimulate additional public comment. NRC will keep the roundtable participants, and the general public, informed of its decision-making process on this issue, and provide opportunities for public comment, including additional meetings such as this.

NRC recently prepared a preliminary draft of the EIS for the Cambridge facility and requested agencies cooperating in its development (Ohio Environmental Protection Agency, Ohio Department of Health, and the U.S. Environmental Protection Agency) to provide comments on this preliminary draft, consistent with their responsibilities under law. This is a

preliminary draft that will be revised, based on these agencies' comments, and issued in the spring of 1996 as a draft for public comment. NRC will be soliciting public comments on the EIS at that time, after consideration and resolution of the cooperating agencies' comments.

#### Conduct of Meeting

The meeting will be held on December 5, 1995, in the Pritchard-Laughlin Civic Center, Cambridge, Ohio. The meeting will begin at 7:00 p.m. and will end at 10:00 p.m. The meeting will be facilitated by F.X. Cameron, NRC's Special Counsel for Public Liaison. The purpose of this meeting is to discuss, with representative stakeholders and the public, information concerning NRC's decommissioning process. The meeting will involve invited representatives from the following groups: NRC, SMC, CFMC, State and local officials, local citizen groups, and the public. These representatives will participate in a facilitated round-table discussion. An agenda for the meeting will be prepared and distributed to all invited representatives, as well as placed in the local public document room, in advance of the meeting. The public will be present during the meeting and time will be provided for public comment. Future information meetings will be held periodically concerning other issues relating to the decommissioning of the Shieldalloy facility and the remediation of offsite contamination.

**FOR FURTHER INFORMATION, CONTACT:** James E. Kennedy, Division of Waste Management, U.S. Nuclear Regulatory Commission, Mail Stop T-7-F-27, Washington, D.C., 20555, telephone (301) 415-6668.

Dated at Rockville, MD this 17th day of November, 1995.

For the U.S. Nuclear Regulatory Commission.

Michael F. Weber,

*Chief, Low-Level Waste and Decommissioning Projects Branch, Division of Waste Management, Office of Nuclear Material Safety and Safeguards.*

[FR Doc. 95-28828 Filed 11-24-95; 8:45 am]

**BILLING CODE 7590-01-P**

#### **Advisory Committee on Reactor Safeguards Subcommittee Meeting on Thermal Hydraulic Phenomena; Notice of Meeting**

The ACRS Subcommittee on Thermal Hydraulic Phenomena will hold a meeting on November 28 and 29, 1995, at the General Electric Nuclear Energy (GENE) Headquarters, 175 Curtner Avenue, San Jose, California.

Most of the meeting will be closed to public attendance to discuss GENE proprietary information pursuant to 5 U.S.C. 552b(c)(4), with the exception of an approximately two-hour session that will be open to the public beginning at 8:30 a.m. on November 28, 1995.

The agenda for the subject meeting shall be as follows:

*Tuesday, November 28, 1995-8:30 a.m. until the conclusion of business.*

*Wednesday, November 29, 1995-8:30 a.m. until the conclusion of business*

The Subcommittee will continue its review of the GENE Test and Analysis Program being conducted in support of the Simplified Boiling Water Reactor (SBWR) passive plant design certification. Discussion topics will include: Revision C of the GENE Test and Analysis Program description document and the SBWR scaling analysis report. The purpose of this meeting is to gather information, analyze relevant issues and facts, and to formulate proposed positions and actions, as appropriate, for deliberation by the full Committee.

Oral statements may be presented by members of the public with the concurrence of the Subcommittee Chairman; written statements will be accepted and made available to the Committee. Electronic recordings will be permitted only during those portions of the meeting that are open to the public, and questions may be asked only by members of the Subcommittee, its consultants, and staff. Persons desiring to make oral statements should notify the cognizant ACRS staff engineer(s) named below five days prior to the meeting, if possible, so that appropriate arrangements can be made.

During the initial portion of the meeting, the Subcommittee, along with any of its consultants who may be present, may exchange preliminary views regarding matters to be considered during the balance of the meeting.

The Subcommittee will then hear presentations by and hold discussions with representatives of GENE, its consultants, and other interested persons regarding this review.

Further information regarding topics to be discussed, whether the meeting has been cancelled or rescheduled, the scheduling of sessions which are open to the public, the Chairman's ruling on requests for the opportunity to present oral statements and the time allotted therefor can be obtained by contacting the cognizant ACRS staff engineer, Mr. Paul A. Boehnert (telephone 301/415-8065) between 7:30 a.m. and 4:15 p.m. (EST) (after November 16, 1995, contact Dr. Medhat El-Zeftawy at 301/415-

<sup>1</sup> Related documents (letters and reports) are available for public review at the Guernsey County District Public Library, 800 Steubenville Avenue, Cambridge, Ohio.